| 產(chǎn)品名稱 | 311-3D4 | 
    
      | 商品貨號 | B161864 | 
      
      | Organism | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) | 
      
      | Cell Type | hybridoma: B lymphocyte | 
      
      | Product Format | frozen | 
      
      | Morphology | lymphoblast | 
      
      | Culture Properties | suspension, but many cells attach | 
      
      | Biosafety Level | 1 
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. | 
      
      | Applications | Animals were immunized with a synthetic polypeptide with the sequence LWEIATYGMSPYPGIDLSQVY(C) corresponding to peptides 429 to 449 of the abl oncogene (formerly 548 to 568 of the v-abl oncogene). In ELISA testing, the antibody reacts with the abl sequence. No binding activity was detected for the homologous region of FES, v-erb B, v-src, SRC, v-yes, RAF-1, v-raf, fms, v-fps, v-ros, HIR, v-mos, and SYN. In immunoblot testing a protein of approximately 40 kd is detected in ANN-1 and src transformed cells. | 
      
      | Derivation | Spleen cells were fused with Sp2/0 myeloma cells. | 
      
      | Genes Expressed | immunoglobulin; monoclonal antibody; against a synthetic abl oncogene peptide | 
      
      | Cellular Products | immunoglobulin; monoclonal antibody; against a synthetic abl oncogene peptide | 
      
      | Comments | Animals were immunized with a synthetic polypeptide with the sequence LWEIATYGMSPYPGIDLSQVY(C) corresponding to peptides 429 to 449 of the abl oncogene (formerly 548 to 568 of the v-abl oncogene). Spleen cells were fused with Sp2/0 myeloma cells. In ELISA testing, the antibody reacts with the abl sequence.  No binding activity was detected for the homologous region of FES, v-erb B, v-src, SRC, v-yes, RAF-1, v-raf, fms, v-fps, v-ros, HIR, v-mos, and SYN. In immunoblot testing a protein of approximately 40 kd is detected in ANN-1 and src transformed cells. The IgG1 reactivity of the antibody with the ABL peptide (429 to 449) was confirmed by ELISA. IgG1 was strongly positive while IgG2b was negative. | 
      
      | Complete Growth Medium | The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002.  To make the complete growth medium, add the following components to the base medium:  fetal bovine serum to a final concentration of 10%. 
 | 
      
      | Subculturing | Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml. Maintain cell density between 2 X 10 exp5 and 1 X 10 exp6 viable cells/ml. Scrape off the attached cells and transfer along with the floating cells into new flasks. | 
      
      | Cryopreservation | culture medium 95%; DMSO, 5% | 
      
      | Culture Conditions | Temperature: 37.0°C | 
      
      | Isotype | IgG1 and IgG2b | 
      
      | Antigenic Determinant | abl oncogene peptide, synthetic | 
      
      | Name of Depositor | National Cancer Institute | 
      
      | Deposited As | mouse (B cell); mouse (myeloma) |